Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma‐like carcinoma
| العنوان: | Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma‐like carcinoma |
|---|---|
| المؤلفون: | Xue-Ning Yang, Xu-Chao Zhang, Yu Chen, Wen-Qing Yan, Wei-Bang Guo, Yi-Long Wu, Zhi Xie, Hui-Bo Feng, Kai Yin, Dan-Xia Lu, Zhi-Yi Lv, Lin-Lin Li |
| المصدر: | Thoracic Cancer, Vol 11, Iss 2, Pp 346-352 (2020) Thoracic Cancer |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, Lung Neoplasms, medicine.medical_treatment, medicine.disease_cause, Tyrosine-kinase inhibitor, Targeted therapy, 0302 clinical medicine, pulmonary lymphoepithelioma‐like carcinoma (PLELC), Carcinoma, Non-Small-Cell Lung, hemic and lymphatic diseases, Medicine, Anaplastic lymphoma kinase, Anaplastic Lymphoma Kinase, Epidermal growth factor receptor, Gene Rearrangement, Mutation, biology, General Medicine, Middle Aged, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, epidermal growth factor receptor (EGFR), ErbB Receptors, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Female, Original Article, Adult, Pulmonary and Respiratory Medicine, Lymphoepithelioma-like carcinoma, Adolescent, medicine.drug_class, lcsh:RC254-282, Young Adult, 03 medical and health sciences, Biomarkers, Tumor, Carcinoma, Humans, Anaplastic lymphoma kinase (ALK), Lung cancer, Aged, Retrospective Studies, business.industry, Original Articles, medicine.disease, 030104 developmental biology, Cancer research, biology.protein, business, Follow-Up Studies |
| الوصف: | Background Primary pulmonary lymphoepithelioma‐like carcinoma (PLELC) is a rare and unique subtype of lung cancer. However, the prevalence of driver alterations, such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, and the response of tyrosine kinase inhibitor (TKIs) in PLELC has not been thoroughly investigated. Method We retrospectively reviewed the genetic profiles and treatment course of 330 PLELC patients at the Guangdong Lung Cancer Institute (GLCI) from 1st January, 2008 to 30th December, 2018. We searched and analyzed related literature published in PubMed and Web of Science from 1st January, 2000 and 31th August, 2019 based on their mention of “driver mutations” and “the response of TKIs to mutant PLELC”. Results Genetic alterations of EGFR/ALK were tested in 203 patients (203/330, 61.5%). Five patients (5/175, 2.9%) had EGFR mutation and three patients (3/140, 2.1%) had ALK alteration. From the total of 15 articles identified from electronic searches, 1071 PLELC cases mentioned the driver mutations. EGFR mutation and ALK rearrangement were detected in 15 patients and one patient, respectively. In total, there were four EGFR/ALK mutant PLELC patients who received targeted therapy as palliative treatment at the GLCI and in the literature. However, there was disease progression in all cases one month after use of TKIs. Conclusion The mutation rates of EGFR and ALK were low in PLELC. EGFR and ALK TKIs showed limited response in EGFR/ALK mutant PLELC. Further studies are needed to explore other molecular targets to optimize the therapeutic strategy for PLELC. |
| اللغة: | English |
| تدمد: | 1759-7706 1759-7714 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b60d4cf36de1a57e97a82ae027e4b8d https://doaj.org/article/e4e7cbc8ccd4460783c53bd2c8389899 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....3b60d4cf36de1a57e97a82ae027e4b8d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17597706 17597714 |
|---|